2-Azabicyclo[2.2.2]octan-5-ol | 794468-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Azabicyclo[2.2.2]octan-5-ol
• CAS: 794468-38-5
• 化学式: C₇H₁₃NO
• mdl: MFCD00218959
• 分子量: 127.186
• InChiKey: ZTHBOFLPBKHZSP-UHFFFAOYSA-N

物化性质

• 沸点：
  229.6±15.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-Azabicyclo[2.2.2]octan-5-ol 在 重铬酸吡啶 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 5-(3,4-dichlorobenzylidene)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Design and synthesis of novel CCR3 antagonists

  摘要：

  As part of our investigation into the development of potent CCR3 antagonists, a series of piperidine analogues was designed and prepared. Exploration of the piperidine core examined both the basicity and the location of a nitrogen, as well as conformational variants. The bicyclo-piperidine 24c was found to be the most potent inhibitor of CCR3 with an IC50 of 0.0082 muM in the binding assay and 0.0024 muM in the chemotaxis assay. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0960-894x(03)00748-0
• 作为产物：
  描述：

  4-硝基水杨酸 在 palladium on activated charcoal 、 rhodium on aluminium lithium aluminium tetrahydride 、 氯化亚砜 、 氢气 作用下， 以 四氢呋喃 、 溶剂黄146 、 乙酸乙酯 、 均三甲苯 为溶剂， 58.0~165.0 ℃ 、365.42 kPa 条件下， 反应 70.0h， 生成 2-Azabicyclo[2.2.2]octan-5-ol
  参考文献：
  名称：

  Design and synthesis of novel CCR3 antagonists

  摘要：

  As part of our investigation into the development of potent CCR3 antagonists, a series of piperidine analogues was designed and prepared. Exploration of the piperidine core examined both the basicity and the location of a nitrogen, as well as conformational variants. The bicyclo-piperidine 24c was found to be the most potent inhibitor of CCR3 with an IC50 of 0.0082 muM in the binding assay and 0.0024 muM in the chemotaxis assay. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0960-894x(03)00748-0

文献信息

• Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists
  申请人：——

  公开号：US20040176416A1

  公开（公告）日：2004-09-09

  Compounds having the formula (I), Ar—(F)(E)-(CR 3 R 4 )—(CHR 5 ) m -(T)-(Q)-Ar 1 , are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar 1 are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is —C(═O)N(R 10 )—, —SO 2 N(R 10 )—, —N(R 11 )C(═O)N(R 10 O)—, —N(R 11 )SO 2 N(R 10 )—, —N(R 11 )C(═S)N(R 10 )—, —N(R 11 )C(═O)—, —N(R 11 )SO 2 —, —N(R 12 )C(═O)CH(R 13 )—, or CH(R 13 )C(═O)N(R 12 )—; Q is —C(═O)— or C 1-2 alkylene; and R 3 , R 4 , R 5 , R 9 , R 10 , R 11 , R 12 , and R 13 are defined as set forth in the specification.

  具有以下化学式的化合物(I)，Ar—(F)(E)-(CR3R4)—(CHR5)m-(T)-(Q)-Ar1，可用作CCR-3受体拮抗剂，其中T是具有一个N原子和一个到两个桥头碳原子的桥接杂环基团；Ar和Ar1是芳基或杂环芳基；F是烷基，烯烃基或键；E是—C(═O)N(R10)—，—SO2N(R10)—，—N(R11)C(═O)N(R10O)—，—N(R11)SO2N(R10)—，—N(R11)C(═S)N(R10)—，—N(R11)C(═O)—，—N(R11)SO2—，—N(R12)C(═O)CH(R13)—或CH(R13)C(═O)N(R12)—；Q是—C(═O)—或C1-2烷基；R3，R4，R5，R9，R10，R11，R12和R13如规范中所述定义。
• Novel anti-diarrheal 4-azatricyclo[4.3.1.1.sup.3,8 ] undecane derivatives
  申请人：G. D. Searle & Co.

  公开号：US04086227A1

  公开（公告）日：1978-04-25

  The present invention, comprehends a method for treating diarrhea comprising administering to an animal in need of anti-diarrheal treatment an effective anti-diarrheal amount of a compound of the formula ##STR1## and acid addition salts thereof wherein Y is alkylene containing 1-4 carbon atoms; R.sub.2 and R.sub.3 together with N is a heterocyclic ring system comprising azamonocyclic ring of the formula ##STR2## wherein Z is phenylhydroxymethylmethylene, phenylhydroxymethylene, phenylcarboxymethylene, phenylcarbalkoxymethylene or azabicycloalkyl or phenyl or hydroxyl substituted azabicycloalkyl containing 6-9 carbon atoms and containing at least 5 atoms in each ring of the azabicycloalkyl or 4-azatricyclo[4.3.1.1.sup.3,8 ]undec-4-yl; Ar.sub.1 and Ar.sub.2 are phenyl, halo-substituted phenyl, (lower alkyl) substituted phenyl, pyridyl, thienyl or furyl, and Ar.sub.3 is phenyl, halo-substituted phenyl, (lower alkyl) substituted phenyl, pyridyl, thienyl, furyl, pyrrolyl, imidazoyl, oxazolinyl, oxazolinyl, thiazolinyl, thiazolyl, 1,2,4-oxodiazolyl, and isoxazolinyl. The present invention also comprehends novel compounds included in the above formula.

  本发明涉及一种治疗腹泻的方法，包括向需要抗腹泻治疗的动物施用有效的抗腹泻化合物，该化合物的化学式为##STR1##以及其酸加成盐，其中Y是含有1-4个碳原子的烷基；R.sub.2和R.sub.3与N一起是一个杂环环系统，包括公式##STR2##的杂氮单环，其中Z是苯基羟甲基亚甲基、苯基羟甲基、苯基羧甲亚甲基、苯基羧基烷氧甲基或含有6-9个碳原子并在每个环中至少含有5个原子的苯基或羟基取代的含氮杂环烷基或4-氮杂三环[4.3.1.1.sup.3,8]十一烷基；Ar.sub.1和Ar.sub.2是苯基、卤代苯基、(较低烷基)取代苯基、吡啶基、噻吩基或呋喃基，Ar.sub.3是苯基、卤代苯基、(较低烷基)取代苯基、吡啶基、噻吩基、呋喃基、吡咯基、咪唑基、噁唑啉基、噻唑啉基、1,2,4-噁唑啉基和异噁唑啉基。本发明还涉及上述化合物中的新化合物。
• Pharmaceutical compounds
  申请人：Heptares Therapeutics Limited

  公开号：US10858352B2

  公开（公告）日：2020-12-08

  This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; X3; X4; R1 R2 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 和/或 M4 受体的激动剂，可用于治疗由毒蕈碱 M1 和 M4 受体介导的疾病。本发明还提供了含有该化合物的药物组合物以及该化合物的治疗用途。所提供的化合物为式 其中 X1；X2；X3；X4；R1 R2 和 R4 如本文所定义。
• CCR-3 RECEPTOR ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1599472A1

  公开（公告）日：2005-11-30
• 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS
  申请人：Ebdrup Soren

  公开号：US20090325932A1

  公开（公告）日：2009-12-31

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11 βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g the metabolic syndrome.